Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
FSRH's response to the Health and Social Care Committee’s Inquiry “Workforce: recruitment, training and retention in health and social care” - submitted in January 2022.
The Royal College of Obstetricians, the British Menopause Society and the Faculty of Sexual and Reproductive Healthcare welcome the opportunity to jointly respond to the APPG Menopause Inquiry – Assessing the impacts of menopause and the case for policy reform.
The Royal College of Obstetricians, the British Menopause Society and the Faculty of Sexual and Reproductive Healthcare welcome the opportunity to jointly respond to the Women and Equalities Committee call for evidence on Menopause in the Workplace.
The Faculty of Sexual and Reproductive Healthcare (FSRH) welcomes the opportunity to submit a response to the call for evidence “Strategic Framework Call for Evidence 2021” by Health Education England (HEE).
FSRH response to Welsh ‘Relationship and sexuality education (RSE) statutory guidance and code’ consultation.
FSRH response to consultation ‘Transforming the public health system: reforming the public health system for the challenges of our times’ by the Department of Health and Social Care (DHSC).
FSRH response to NHS Confederation survey on leadership in Integrated Care Systems
Joint FSRH and RCOG response to the Health and Social Care Committee Inquiry into the White Paper “Integration and Innovation: working together to improve health and social care”.
We respond to the consultation by The Medicines and Healthcare Products Regulatory Agency (MHRA) on whether to reclassify Lovima, a progestogen-only contraceptive pill, as Pharmacy (P) medicine.
We respond to the consultation by The Medicines and Healthcare Products Regulatory Agency (MHRA) on whether to reclassify Hana, a progestogen-only contraceptive pill, as Pharmacy (P) medicine.
